Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of SYH2066 in adults with RSV respiratory tract infection
CTR20263533Phase 2Active
- Sponsor
- CSPC Ouyi Pharmaceutical
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SYH2066 in respiratory syncytial virus disease (RSV), sponsored by CSPC Ouyi Pharmaceutical. Started Sep 2026; status: active.
02
Drugs
SYH2066
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on CTR20263533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263533.